Regeneron Pharmaceuticals (REGN)

• Market cap: $59.9B
• 1 day: 0.99%
• 5 days: 1.53%
• 1 month: -2.56%
• 3 months: 8.2%
• 6 months: -16.64%
• Year to date: -20.92%
• 1 year: -50.95%
• 5 years: -2.48%
• 10 years: 4.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,207

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

14% more call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.01B

7% less repeat investments, than reductions

Existing positions increased: 436 | Existing positions reduced: 471

1.44% less ownership

Funds ownership: 85.54% [Q1] → 84.1% (-1.44%) [Q2]

7% less funds holding

Funds holding: 1,273 [Q1] → 1,189 (-84) [Q2]

20% less capital invested

Capital invested by funds: $58.3B [Q1] → $46.8B (-$11.5B) [Q2]

20% less funds holding in top 10

Funds holding in top 10: 15 [Q1] → 12 (-3) [Q2]

33% less first-time investments, than exits

New positions opened: 133 | Existing positions closed: 199

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $584
• Avg. target: $752
• High target: $850

9 analyst ratings

• positive: 7 78%
• neutral: 2 22%
• negative: 0 0%

Bernstein William Pickering	$781	Outperform Maintained	27 Aug 2025
Jefferies Akash Tewari	$831	Buy Maintained	27 Aug 2025
Truist Securities Srikripa Devarakonda	$812	Buy Maintained	11 Aug 2025
BMO Capital Evan David Seigerman	$640	Outperform Maintained	4 Aug 2025
Morgan Stanley Matthew Harrison	$761	Overweight Maintained	4 Aug 2025